Effects of recombinant porcine somatotropin on growth and carcass traits in meishan pigs

Effects of recombinant porcine somatotropin (rpST) on growth, feed intake, feed conversion, back-fat thickness and lean percentage were examined in growing Meishan pigs. The experiment comprised 42 barrows of which 20 were administered 14 mg rpST twice a week i.m., starting at 40 kg, the others received a placebo. Pigs were fed ad libitum a diet containing 9.2 MJ net energy and 156 g crude protein kg⁻¹ and were slaughtered at 90 kg liveweight. From 40 to 90 kg liveweight, rpST effects were: daily gain +17.9%; feed intake −5.1%; feed conversion −17.5%; backfat thickness −29.8%; lean percentage +16.0%. The effects of rpST in Meishan are much larger than in a similar experiment with leaner western pigs. Development of synthetic breeds with Meishan in combination with the use of rpST in cross-bred fattening pigs may be a way to economically exploit the high fertility of Meishan.     

Effect of recombinant porcine somatotropin on growth and carcass quality in growing pigs: interactions with genotype, gender and slaughter weight

Effects of recombinant porcine somatotropin (rpST) on growth, lean tissue growth, feed intake, feed conversion, lean tissue feed conversion, backfat thickness and lean percentage were examined in 96 growing pigs. The experiment used barrows and gilts from the genotypes Duroc, F1 (Dutch Yorkshire x Dutch Landrace) and Pietrain. Half the pigs received 14 mg rpST i.m. twice each week starting at 60 kg; others received a placebo. Pigs had ad libitum access to a diet containing 2,162 kcal net energy and 182 g crude protein per kilogram and were slaughtered at either 100 or 140 kg live weight. From 60 to 100 and from 100 to 140 kg, live weight responses to rpST averaged as follows: daily gain, +4.5 and +19.9%; feed intake, -4.4 and +3.5%; feed conversion, -8.4 and -13.9%; backfat thickness, -13.8 and -22.8%; lean percentage, +4.4 and +8.7%; lean tissue growth rate, +8.6 and +35.8%; and lean tissue feed conversion, -13.1 and -24.9%. No gender x rpST interaction was detected. However, a genotype x treatment interaction was significant for backfat thickness at both slaughter weights, showing a higher response to rpST in Duroc than in Pietrain and F1. Growth performance was improved more by rpST in F1 and Pietrain than in Duroc, especially at higher weights, but carcass traits were improved more by rpST in Duroc. The response to rpST in lean tissue growth rate from 60 to 100 kg was highest in fatter animals (Duroc, barrows), whereas from 100 to 140 kg, response in lean tissue growth rate to rpST was highest in leaner animals (Pietrain, F1, gilts).     

Influence of dietary protein and recombinant porcine somatotropin administration in young pigs: growth, body composition and hormone status

The influence of dietary protein and recombinant porcine somatotropin (rpST) administration on growth and body composition was investigated in barrows. Ten groups of six pigs starting at 30 kg were restrictively fed (approximately 80% of ad libitum) one of five diets containing 11, 15, 19, 23 or 27% protein. Diets contained skim milk (12%). Soybean meal diluted with cornstarch was used as the supplemental source of dietary protein. Diets were isocaloric (3.8 Mcal DE/kg) and all contained the same amount of lysine (18 to 20 g/kg). Thirty pigs were treated daily with rpST (100 micrograms/kg) by i.m. injection; the remaining pigs were treated with sterile diluent (control) for 42 d. Growth rate was greater in rpST-treated pigs at all levels of protein intake; however, the magnitude of the response to rpST treatment was lowest among pigs fed the diet containing 11% protein. Feed:gain ratio, backfat depth and carcass fat content were decreased in rpST-treated pigs compared to respective controls. Additionally, the concentration of carcass fat decreased concomitantly with an increase in dietary protein intake. Concentration of carcass protein increased linearly as dietary protein increased in control and rpST-treated pigs. In contrast, treatment with rpST was associated with an increased visceral mass; the concentration of protein and fat in the viscera was influenced by protein intake but not by rpST. These results, characterized by few treatment interactions, suggest that when energy intake is kept constant and appropriately fed pigs serve as controls, dietary protein and rpST influence growth and body composition by independent mechanisms.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effects of frequency of recombinant porcine somatotropin administration on growth performance, tissue accretion rates, and hormone and metabolite concentrations in pigs.

Thirty-two crossbred barrows were used to determine the effects of frequency of administration of equivalent total dosages of recombinant porcine somatotropin (rpST) on growth performance, tissue accretion rates, and hormone and metabolite status of pigs. Treatments were control (buffer-injected daily), 60 micrograms/kg BW daily (4 injections/4 d), 120 micrograms/kg BW injected every other day (2 injections/4 d), or 240 micrograms/kg BW given every 4th d (1 injection/4 d). Treatments were initiated at 35 BW and continued until each pig had consumed a total of 440 Mcal of DE intake. Pigs were fed a diet that contained 16% CP, 1.2% lysine, and 3.5 Mcal of DE/kg at 85% of calculated ad libitum intake. Feed intake and rpST dose were adjusted at 8-d intervals. The 240 micrograms/kg BW treatment did not decrease appetite beyond the 15% restriction already imposed in the experimental design. Treatment groups responded to rpST in a frequency-dependent manner. Average daily gain was improved by 10, 23, and 36%, respectively, as injection frequency was increased from 1/4 to 2/4 to 4/4 d. Muscle weights were increased uniformly (15% on average) on a BW basis by all rpST treatments. Carcass (21, 42, and 63%), visceral (43, 65, and 112%), and empty body (22, 43, and 65%) protein accretion rates were increased by rpST treatment in a frequency-dependent fashion, respectively. Lipid accretion also was reduced in carcass and empty body (31% on average) by all rpST injection schemes relative to controls; however, visceral lipid accretion was increased by 59% by rpST. Protein utilization efficiency increased linearly by 24, 45, and 65% as the frequency of injection of rpST was increased from 1/4 to 2/4 to 4/4 d. Hormones and metabolites exhibited frequency-related profiles as well. These results suggest that frequency of administration greatly influences the magnitude of responsiveness to rpST and that optimal benefit would be realized by a delivery system that mimicked a daily surge, at minimum, of rpST.     

Effect of recombinant porcine somatotropin on lactational performance and metabolite patterns in sows and growth of nursing pigs

Sixteen crossbred sows (Yorkshire x Duroc) were used to determine the effect of recombinantly derived porcine somatotropin (pST) on lactational performance and the pattern of plasma metabolites and growth rate of nursing pigs. Daily s.c. injections of either pST (8.22 mg.sow-1.d-1) or excipient were administered at 1000 on d 12 through d 29 of lactation. Jugular cannulas were inserted in three sows/treatment and hourly blood samples were collected on d 11 to 13 and d 28 to 29 of lactation to determine the effect of treatment on plasma concentrations of somatotropin, glucose and nonesterified fatty acids in plasma. Milk production and weight of nursing pigs were determined pretreatment (d 9 and 10) and on d 16, 22 and 28. Milk production of sows receiving pST progressively increased above that of control sows and was 22% greater on d 28. Milk composition was not affected by treatment with pST (P greater than .10), so that the increase in yields of milk fat, lactose and solids paralleled the increases in milk yield. Total milk protein yield tended to be higher in sows receiving pST, but protein yield was greater (P less than .10) only on d 28. Pigs suckling sows treated with pST weighed .34 kg more at the end of the lactation period (P less than .05). Sows receiving pST consumed less feed (P less than .05) during the treatment period, and, as a result, lost more weight (P less than .10) and backfat (P less than .05) than control sows. Average concentrations of plasma somatotropin were elevated approximately 2.5-fold above baseline levels by exogenous pST. No acute alterations in plasma glucose or nonesterified fatty acids were observed in response to pST treatment, however, sows receiving pST had a chronic elevation of plasma glucose on d 29 of lactation.     

Effects of porcine growth hormone on glucose metabolism of pigs: I. Acute and chronic effects on plasma glucose and insulin status

The acute and chronic effects of porcine growth hormone (pGH) administration on glucose homeostasis of pigs were investigated in the present study. Twelve Yorkshire barrows (average BW = 65 kg) fitted with femoral artery catheters were allotted to three groups. Pigs received acute, intra-arterial injections of either pituitary pGH, a recombinantly derived pGH analog (ppGH or rpGH, 100 micrograms/kg BW) or saline. Acute injection of pGH did not affect fasting plasma glucose or insulin status. Pigs then were treated daily by i.m. injection for 24 d with 70 micrograms ppGH/kg BW. Serum glucose and insulin concentrations during the fed and fasted states were higher in pGH-treated than in control pigs. On d 25, an acute intra-arterial injection of ppGH (100 micrograms/kg BW) elicited increases in plasma glucose and insulin in pigs chronically treated with pGH. The area circumscribed by the glucose and insulin response curves 5 min to 7 h postinjection was 40% (P less than .005) and 177% (P less than .001), respectively, higher in ppGH-treated than in control pigs. These data indicate that pGH does increase plasma glucose and insulin in the fed and fasted states; however, this response is only observed after chronic pGH administration. In addition, pGH is capable of increasing plasma glucose and insulin acutely in the pig. This effect, however, only is observed in pigs treated chronically with pGH. The mechanisms by which pGH elicit these effects on glucose homeostasis are not known.     

Effects of recombinant porcine somatotropin on metabolic rate in growing pigs

Effects of recombinant porcine somatotropin (rpST) on metabolic rate were studied in two trials with 24 crossbred barrows (Yorkshire x Landrace) in each. The barrows weighed about 80 kg (SE within trials 2.2 kg) at the start of the measurements and in each trial 12 pigs received 4 mg of rpST and 12 received a placebo. The diet contained 2.57 Mcal NE/kg and 20% CP (about 1% lysine). Animals were fed approximately 2.8 times maintenance (280 kcal ME.kg-.75.d-1). Heat production (gaseous exchange of CO2 and O2) and activity were measured continuously. Heat production associated with activity was calculated from the regression of heat production on activity. Animals treated with rpST exceeded controls in rate of gain by 252 g/d (P less than .001) and in metabolic rate by 14.5 kcal.kg-.75.d-1 (P less than .01). The rpST treatment increased rectal (+ .2 degrees C) and surface (+ .8 degrees C) temperatures. Activity-related heat production in treated pigs was increased, but this was only partly related to the increase in metabolic rate with rpST. The daily patterns of total and activity-related heat production were similar between pigs in both experimental treatments.     

Interactions between environmental temperature and porcine growth hormone (pGH) treatment in neonatal pigs

Age-dependent interactions between environmental temperature and porcine growth hormone (pGH) treatment on the function of the somatotrophic axis were evaluated in the neonatal pig. At 3 d of age, 40 Landrace x Yorkshire x Duroc piglets received intraperitoneal implants containing either recombinant pGH (0.5 mg/d; n = 20) or vehicle (control; n = 20). Piglets were maintained at either a low (21 degrees C, 50% relative humidity; n = 20) or high (32 degrees C, 50% relative humidity; n = 20) temperature. At 4 and 6 wk of age, 5 pGH-treated and 5 control piglets from each thermal group were sacrificed for tissue collection. Blood samples were collected at the time of sacrifice and analyzed for serum concentrations of GH, insulin-like growth factor 1 (IGF-1), and IGF-2. Liver RNA was analyzed for mRNAs specific for the GH receptor, IGF-1, IGF-2, and IGF binding protein 3. There was no effect of pGH treatment (P = 0.4) on average daily gain; however, both age (P = 0.002) and temperature (P = 0.001) had an effect on average daily gain such that those animals maintained at a low temperature and those sacrificed at 6 wk had greater average daily gains. Serum concentration of GH was elevated (P = 0.003) by pGH treatment and was lowest in the 6-wk-old group (P = 0.008). Serum concentration of IGF-1 was elevated (P = 0.007) by pGH treatment and increased with age (P = 0.01). Liver GH receptor mRNA was unaffected (P > 0.5) by pGH treatment, but was greater in the 6-wk-old group (P < 0.0001) and in piglets maintained at the high temperature (P = 0.04). IGF-1 mRNA was enhanced by pGH treatment (P = 0.0003) and by exposure to the high temperature (P = 0.04), but did not differ (P > 0.5) between age groups. IGF-2 mRNA was greater (P = 0.0009) in the 4-wk-old group and in piglets maintained at the high temperature (P = 0.007), but was unaffected (P = 0.5) by pGH treatment. IGF binding protein 3 mRNA increased with age (P = 0.0004) and was stimulated by pGH treatment in the 6-wk-old group (P = 0.034). The relatively lower level of GH receptor and IGF mRNAs in conjunction with greater growth in the cold environment suggests that somatotrophic gene expression in the liver is not rate limiting for growth in the neonatal pig.     

Growth performance and carcass characteristics of pigs administered recombinant porcine somatotropin during 30 to 110 kilogram live weight

To determine growth performance during and after injection of recombinant porcine somatotropin (rpSt), crossbred Yorkshire gilts and barrows (n = 54/gender, 27 to 42 kg BW) were blocked by BW and gender (n = 3 blocks/gender). Within each block, three pigs/gender were assigned randomly to each of six pens/block. A diet containing 24.8% CP was fed ad libitum. During the live weight period of 30 to 110 kg, pigs either remained as controls (one pen/block) or were injected (i.m.) daily with rpSt (120 micrograms/kg BW) during either 30 to 60, 30 to 100, 30 to 110, 60 to 100 or 60 to 110 kg BW. Thus, three gilts and three barrows in each of three pens received each treatment. Pigs were slaughtered at either 60 kg BW (1 d after rpSt injection) or 110 kg BW (1 d, 10 d or 70 d after rpSt injection). Relative to controls, pigs injected with rpSt exhibited faster and more efficient growth during the injection period (P less than .05) but slower and less efficient growth during 10 d after cessation of injection (P less than .05). Carcasses of pigs slaughtered 1 d or 10 d after rpSt injection were leaner than controls (P less than .05), but among the pigs treated with rpSt, carcasses of pigs withdrawn from rpSt for 10 d contained more fat (P less than .05) and had a lower percentage of muscle (P less than .05) than carcasses of pigs withdrawn from rpSt for 1 d. Growth and carcass measurements were similar (P greater than .05) between controls and pigs killed 70 d after rpSt injection.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effects of gender and genotype on the response of growing pigs to exogenous administration of porcine growth hormone

Sixty crossbred pigs (Large White x Landrace) were used in a 2 x 2 x 2 factorial experiment to investigate the effects of gender (intact males vs females) and strain (A vs B) on the response to exogenous porcine growth hormone (pGH) administration (0 [excipient-treated] vs .1 mg pGH.kg live weight-1.d-1). All pigs had ad libitum access to their diet; pGH was administered daily from 60 to 90 kg live weight. All aspects of growth performance and body composition were affected to different degrees by gender and pGH. Strain A pigs had a higher capacity for protein accretion, superior growth performance and contained less fat in the eviscerated carcass and empty body compared with Strain B pigs. Within each strain, intact males ate more feed, had a higher rate of protein deposition and exhibited faster and leaner growth than females. Exogenous pGH administration increased average protein deposition and growth rate by 84 and 34%, respectively, and reduced average feed intake, fat deposition rate, feed:gain and carcass fat content by 14, 59, 37 and 33%, respectively. The magnitude of the changes in growth performance, tissue accretion rates and body composition elicited by pGH were independent of strain. However, within each strain the improvement in feed:gain and reduction in carcass fat measurements elicited by pGH were proportionately larger for females than for intact males.     

Interaction of dietary protein content and exogenous porcine growth hormone administration on protein and lipid accretion rates in growing pigs

Sixty-six intact male pigs were used to investigate the relationships between exogenous porcine growth (pGH) administration (0, excipient-treated, and .09 mg recombinant pGH.kg-1.d-1) and dietary protein content (8.3, 11.4, 14.5, 17.6, 20.7 and 23.8%) on protein and lipid accretion rates over the live weight range of 30 to 60 kg. Feed intakes were restricted (1.84 kg.pig-1.d-1) and pGH was administered daily by i.m. injection. Rate of protein deposition increased with increasing dietary protein up to 17.6 and 20.7%, respectively, for control and pGH-treated pigs; both growth and protein deposition were enhanced by pGH on the four higher protein diets but remained unaffected by pGH administration to pigs given the two lowest protein diets. Plasma IGF-I concentration was elevated by pGH administration in pigs given the four higher protein diets but unaffected by pGH with the two lowest protein diets. Rate of fat deposition was depressed on all dietary protein treatments by pGH administration; carcass fat content of control and pGH-treated pigs declined with each increase in dietary protein up to 17.6 and 23.8%, respectively. The results demonstrate that pGH acts independently on protein and lipid metabolism.     

Stimulation of swine growth by porcine growth hormone

Highly purified porcine growth hormone (pGH; USDA-B1) was administered by im injection (22 micrograms X kg body weight-1 X d-1) to rapidly growing Yorkshire barrows for 30 d. Growth hormone significantly increased growth rate (10%), feed efficiency (4%), cartilage growth and muscle mass. However, pGH did not affect carcass adipose tissue mass. Intramuscular lipid content of the longissimus was increased 50% by pGH administration. Plasma pGH concentration was elevated (7- to 11-fold) for 3 to 5 h post-injection. Chronic administration of pGH depressed pituitary GH content and concentration approximately 45%. No GH antibodies were detected in the plasma of GH-treated swine. Plasma somatomedin-C concentration was increased 55% by GH treatment 3 h post-injection. Plasma glucose and insulin concentrations were both significantly increased in GH-treated swine, suggesting that the animals had developed a state of insulin resistance. Plasma-free fatty acid concentration tended to be higher in GH-treated animals. Treatment of swine with pGH significantly decreased plasma blood urea nitrogen. Assessment of animal health during the trial and postmortem indicated that pGH administration did not have any adverse effects. In summary, treatment of young, rapidly growing swine with pGH stimulated growth performance without affecting animal health or inducing the production of GH antibodies.     

Determination of the temporal relationship between porcine growth hormone, serum IGF-1 and cortisol concentrations in pigs

We found previously that porcine growth hormone (pGH) causes an increase in growth rate with a concurrent improvement in carcass composition in pigs. The somatomedin, insulin-like growth factor 1 (IGF-1), is though to play a major role in mediating some of the anabolic actions of GH, while the glucocorticoid hormones are potential counter-regulators of these effects. The present study was conducted to determine the temporal and dose-response relationship between GH administration and serum IGF-1 and cortisol concentrations in pigs. Twelve Yorkshire barrows, fitted with femoral artery catheters, were injected (im) with either 0, 10, 100 or 1,000 micrograms/kg pGH. Blood sampling began 40 min prior to pGH injection and was continued for 37 h. Serum GH, IGF-1 and cortisol concentrations were determined by radioimmunoassay. In control animals, serum GH concentrations ranged from 1.6 to 5.7 ng/ml over 37 h. In the animals treated with increasing doses of pGH, peak serum GH concentrations reached 28, 112 and 286 ng/ml and levels remained elevated for 4, 12 and 24 h, respectively. Serum IGF-1 concentrations were elevated by pGH after a lag time of 4 to 6 h. When the IGF-1 concentrations were integrated over time, the response appeared to be dose-dependent, with an ED50 of 710 micrograms/kg body weight (BW). Data for serum cortisol concentrations showed a great deal of individual variation. A transient increase in cortisol was observed, but only in the group treated with 1,000 micrograms pGH/kg BW. Cortisol levels returned to baseline 2 h after pGH injection.(ABSTRACT TRUNCATED AT 250 WORDS)     

Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs

Ghrelin has been implicated in the control of food intake and in the long-term regulation of body weight. We theorize that preventing the ability of ghrelin to interact with its receptors, would eventually lead to decreased appetite and thereby decrease body weight gain. To test our hypothesis, pigs were actively immunized against ghrelin. Ghrelin((1-10)) was conjugated to BSA and emulsified in Freund's incomplete adjuvant and diethylaminoethyl-dextran. Primary immunization was given at 19 weeks of age (WOA), with booster immunizations given 20 and 40 days after primary immunization. Body weight (BW) and plasma samples were collected weekly beginning at 19 WOA, and feed intake was measured daily. Fourteen days after primary immunization, the percentage of bound (125)I-ghrelin in plasma from immunized pigs was increased compared with control animals (P<0.001). Voluntary feed intake was decreased more than 15% in animals that were actively immunized against ghrelin compared with controls. By the end of the experiment, immunized pigs weighed 10% less than control animals (P<0.1). Concentrations of GH were increased (P<0.05) in immunized pigs. Apoptosis was not observed in post-mortem samples obtained from the fundic region of the stomach. Our observations suggest that immunization against ghrelin induces mild anorexia. This procedure could potentially be used as a treatment to control caloric intake and obesity.     

Pituitary porcine growth hormone (pGH) and a recombinant pGH analog stimulate pig growth performance in a similar manner

This study was conducted to establish the extent to which different doses of pituitary porcine growth hormone (ppGH) increase pig growth performance. Pigs were treated daily for 11 wk with 0, 35 or 70 micrograms ppGH/kg BW. In addition, these effects were compared with those produced by treating pigs with 0, 35, 70 or 140 micrograms.kg BW-1.d-1 of a recombinantly derived analog of porcine growth hormone (rpGH). This analog lacks the first seven amino acids at the NH2 terminus. Growth rate was increased similarly by ppGH and rpGH (the maximal increase was 19%). Feed efficiency was improved by ppGH and rpGH (the maximal response was 25%). This improvement in feed efficiency was associated with a decrease in feed intake (17% with the largest dose of rpGH). Both ppGH and rpGH decreased adipose tissue growth and increased muscle mass. Carcass lipid was decreased by 68% in pigs treated with the largest dose of rpGH. The recombinant pGH analog appeared to be less potent than ppGH in decreasing adipose tissue growth rate. All other parameters measured, however, indicated that rpGH mimicked the biological effects of ppGH (including binding to pig liver membranes and induction of insulin-like growth factor I production). Sensory panel evaluations indicated that neither ppGH nor rpGH affected pork palatability. Larger doses of pGH (greater than 70 micrograms/kg BW) adversely affected pig mobility. This impairment in mobility appears to be due to osteochondrosis. Our findings establish that the rpGH analog is equipotent to ppGH in stimulating growth performance and that pigs can be treated without any significant adverse effects when they are treated with less than 70 micrograms of pGH.kg BW-1.d-1.     

The effects of bovine recombinant growth hormone administration on insulin-like growth factor-I and the haemopoietic system in thoroughbred geldings

The effect of intramuscularly administered recombinant bovine growth hormone (rbGH) on insulin-like growth factor-I (IGF-I) and white and red blood cell indices was studied in Thoroughbred geldings. An insulin-like growth factor binding protein (IGFBP)-blocked radioimmunoassay was modified and validated for the measurement of IGF-I in equine blood plasma. Baseline values of IGF-I and blood indices were determined over a 48 h period and then a single dose of 5 microg/kg, 10 microg/kg or 50 microg/kg of rbGH was administered. Insulin-like growth factor-I levels increased in a dose-dependent manner, with the highest values between 12 h and 24 h. The highest dose (50 microg/kg) yielded the greatest IGF-I response with a 90.2+/-10.8% increase at 24 h. White blood cell count increased following the three doses of rbGH with the highest white blood cell count at 12 h after the 50 microg/kg dose. Haemoglobin was significantly increased at 24 h (P< 0.05), when values following doses of 10 microg/kg and 50 microg/kg were significantly greater than after the vehicle or the dose of 5 microg/kg. Red blood cell count was not affected by any of the rbGH doses. These results indicated that rbGH is biologically active in the horse and that rbGH at a dose rate of 10 microg/kg or more could be used therapeutically.     

Castration and testosterone effects on endogenous and somatocrinin-induced growth hormone release in intact and castrated male pigs

Growth hormone (GH) release is influenced mainly by two hypothalamic factors, growth hormone-releasing factor (GRF) and somatostatin and is modulated by other hormones such as gonadal steroids. The objective of this study was to determine if castration (CA) and exogenous testosterone (TE) affect endogenous and GRF-induced GH release. Purebred Yorkshire male pigs (n = 32) were assigned to one of the following treatments: T1:CA; T2:CA +/- TE; T3: intact (IN); T4: IN +/- TE, in a 2 x 2 factorial design. Piglets were castrated at 3 days of age. Testosterone propionate (1.0 mg/kg) in sesame oil (2 ml) or sesame oil alone was injected sc SID during a 10-day period before each sampling day at 9, 15 and 21 weeks of age. Jugular blood samples were collected for a 6-hr period preceding and following iv injection of hGRF (1-29)NH2 (10 micrograms/kg). These procedures were repeated at 9, 15 and 21 weeks of age. The overall mean GH levels and the area under the GH peaks before and after GRF stimulation were lower (P less than .05) in castrated animals than in intact animals. Testosterone treatment increased (P less than .05) circulating TE levels and increased the amplitude of the endogenous GH peaks but did not affect (P greater than .05) the GRF-induced GH release. Increasing age produced a marked reduction of the amplitude of the GH peaks, the area under the GH peaks, the baseline mean and the overall mean GH levels during the 6-hr period preceding GRF injection. The present data support the hypothesis that castration in pigs reduces circulating and GRF-induced GH release. Exogenous testosterone for 10 days did not stimulate endogenous or GRF-induced GH release with the exception of the amplitude of the endogenous GH peaks.     

猪繁殖与呼吸综合征DNA重组质粒对猪的免疫效应

猪繁殖与呼吸综合征病毒(PRRSV)灭活疫苗、表达GP5蛋白的DNA重组质粒分别与表达IL-2和IL-4的重组质粒(pcDNA-IL-2和pcDNA-IL-4)联合免疫健康仔猪,经3次免疫后人工感染PRRSV HB-2株,检测仔猪体液免疫以及攻毒保护性反应。研究结果显示,重组质粒pCI-GP5可诱导免疫猪产生抗GP5抗体,最高ELISA抗体效价可达1∶285。攻毒后组织中PRRSV核酸的检出率下降30.3%,与对照组相比,差异显著(P<0.05),表明表达PRRSV GP5的DNA重组质粒pCI-GP5可诱导一定的免疫效力。pcDNA-IL-2与pCI-GP5联合免疫后,病毒血症的出现频率减少38.9%,PRRSV阳性组织检出率下降28.8%,与对照组差异显著(P<0.05);pcDNA-IL-4与pCI-GP5联合免疫后,最高ELISA抗体效价可达1∶320,病毒血症的出现频率下降38.9%,PRRSV阳性组织检出率减少34.8%,与对照组相比差异极显著(P<0.01)。本研究表明,PRRS DNA重组质粒pCI-GP5对猪的免疫保护力是稳定的,真核表达的细胞因子pcDNA-IL-2与pcDNA-IL-4能够显著增强pCI-GP5的免疫保护力。